Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK reaffirms 2026 guidance after strong first-quarter performance
03:04am, Wednesday, 29'th Apr 2026
GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 pharmaceuticals giant, has reiterated its full-year 2026 guidance after delivering a strong first quarter, with core operating profit growth and earnings per
GSK Earnings Boosted by Higher Specialty Medicine Sales
02:45am, Wednesday, 29'th Apr 2026
The pharmaceutical giant said core operating profit for the first quarter was £2.65 billion compared with £2.53 billion for the same period a year earlier.
GSK beats quarterly profit estimates on strength in respiratory, general medicines
02:06am, Wednesday, 29'th Apr 2026
British drugmaker GSK reported first-quarter profit above analysts' expectations on Wednesday, helped by strong sales of its respiratory and other general medicines.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Appl
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:05am, Monday, 27'th Apr 2026
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio
03:58am, Monday, 27'th Apr 2026
GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a Delaware court dismissed a counterclaim brought by...
88 Energy and Burgundy amend Phoenix arrangements
03:46am, Monday, 27'th Apr 2026
88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) has tightened its contractual position at Project Phoenix in Alaska while giving joint venture...
Bango targets positive cash earnings from subscriptions division in 2027 after strong start to year
03:23am, Monday, 27'th Apr 2026
Bango PLC (AIM:BGO, OTCQX:BGOPF), the payments and subscriptions technology company, has set a target for its subscriptions division to achieve positive...
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio
03:01am, Monday, 27'th Apr 2026
GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a Delaware court dismissed a counterclaim brought by AnaptysBio, the US biotechnology company, in a
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Recommendation of “Reduce” by Brokerages
02:38am, Monday, 27'th Apr 2026
Shares of GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the ten analysts that are currently covering the stock, Marketbeat.com repo
Top FTSE 100 shares to watch next week: Lloyds, Barclays, GSK, Natwest
03:28am, Friday, 24'th Apr 2026
The FTSE 100 Index pulled back this week as the US-Iran war continued and after the UK published a hot consumer inflation report. It dropped to £10,365 from this month's high of £10,687.
FTSE 100 Index retreats ahead of Lloyds, Barclays, Natwest, GSK earnings
05:50am, Thursday, 23'rd Apr 2026
The FTSE 100 Index pulled back for three consecutive days as companies exposed to the ongoing US-Iran war slipped and as the UK published a strong inflation report. It also dropped as market partici
GSK (GSK) Earnings Expected to Grow: Should You Buy?
11:02am, Wednesday, 22'nd Apr 2026
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
09:15am, Monday, 20'th Apr 2026
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its f
GSK: 'Strong Buy' On Mo-Rez Oncology Expansion Potential
07:42am, Sunday, 19'th Apr 2026
GSK maintains a 'Strong Buy' rating, driven by robust Oncology portfolio growth and promising pipeline catalysts. The company's BLENREP is regaining traction in multiple myeloma, outperforming JNJ's D
